Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: A case report and proposed molecular pathways

11Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

A 42-year-old Caucasian female with history of neurofibromatosis type 1 presented with nephrotic range proteinuria and focal segmental glomerulosclerosis (FSGS). On final dose of lisinopril 20 mg/day, protein-creatinine ratio declined to 0.33 within 10 months. We propose the hypothesis that development of FSGS in NF1 may be mediated by activation of mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) signaling pathways secondary to up-regulation of ras proteins due to deficient neurofibromin. Since mTOR signaling pathway is partially mediated through angiotensin-II activation, angiotensin-converting enzyme (ACE) inhibition may serve as an effective initial treatment beyond anti-proteinuric properties of ACE-inhibitors. © 2013 The Author.

Cite

CITATION STYLE

APA

Afshinnia, F., Vega-Warner, V., & Killen, P. (2013). Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: A case report and proposed molecular pathways. Clinical Kidney Journal. Oxford University Press. https://doi.org/10.1093/ckj/sft010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free